Troglitazone is an oral antidiabetic drug that is a ligand for peroxisome proliferator activated receptor γ (PPARγ). Based on other studies that have implicated an immunosuppressive role for PPARγ during inflammatory responses, we hypothesized that troglitazone treatment would improve survival in a murine model of endotoxemia and that the protective effect would be mediated by decreased expression of inflammatory mediators. C57Bl/6N x Sv/129 (wild-type [WT]) or PPARα null mice treated for 2 weeks with dietary troglitazone (0.1%) had significantly fewer deaths and a higher LD 50 value compared to control-fed mice when challenged with lipopolysaccharide (LPS). PPARα null mice were more sensitive to the lethal effects of LPS as evidenced by a 2-fold lower LD 50 (6.6 mg/kg) compared to WT mice (14.6 mg/kg). Troglitazone treatment had no significant effect on LPS-induced plasma TNF, glucose, or nitric oxide levels in WT or PPARα null mice at any of the time points examined. However, troglitazone treatment significantly reduced LPS-induced plasma IL-6 levels in both WT and PPARα null mice. The results of these studies suggest that troglitazone treatment protects mice against a lethal challenge of LPS, but whether or not this effect is mediated through decreased expression of inflammatory mediators remains unclear.
References
1.
Parker M.Cardiac dysfunction in human septic shock. Ann Intern Med1990; 113: 227—242.
2.
Pawelec G., Adibzadeh M., Pohla H. et al. Immunosenescence: aging of the immune system. Immunol Today1995; 16: 420—422.
3.
Beutler B., Milsark I Cerami A.Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science1985 ; 229: 869—871.
4.
Tracey K., Fong Y., Hesse D. et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature1987; 330: 662—664.
5.
Green S.PPAR: a mediator of peroxisome proliferator action. Mutat Res1995; 333: 101—109.
6.
Schoonjans K. , Staels B., Auwerx J.The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation . Biochim Biophys Acta1996; 1302: 93—109.
7.
Gimble J., Hua X., Wanker F. et al. In vitro and in vivo analysis of murine lipoprotein lipase gene promoter: tissue-specific expression. Am J Physiol1995; 268: E213—E218.
8.
Kliewer S., Lenhard JM, Willson TM et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell1995; 83: 813—819.
9.
Hill M., Clarke S., Rodgers K. et al. Effect of PPAR alpha activators on TNF expression in mice during endotoxemia. Infect Immun1999; 67: 3488—3493.
10.
Jiang C., Ting AT, Seed B.PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines . Nature1998; 391: 82—86.
11.
Ricote M., Li AC, Willson TM et al. The peroxisome proliferator-activated receptor gamma is a negative regulator of macrophage activation. Nature1998; 391: 79—82.
12.
Hill MR, Stith RD, McCallum REInterleukin-1: a regulatory role in glucocorticoid-regulated hepatic metabolism . J Immunol1986; 137: 858—862.
13.
Hill MR, Young MD, McCurdy CD et al. Decreased expression of murine PPARγ in adipose tissue during endotoxemia. Endocrinology1997; 138: 3073—3076.
14.
McCallum RE , Berry LJEffects of endotoxin on gluconeogenesis, glycogen synthesis, and liver glycogen synthase in mice. Infect Immun1973; 7: 642—654.
15.
McCallum RECarbohydrate metabolism in experimental endotoxemia. In: Urbaschek B, Urbaschek R , Neter E. (eds) Gram-negative Bacterial Infections. Pathophysiological, Immunological, and Clinical Aspects . New York: Springer, 1975; 281-287.
16.
McCallum RE , Pontious MLCarbohydrate metabolism in C3H/HeJ (non-responder) mice during endotoxic shock. Adv Shock Res1979; 2: 113—127.
17.
Akira S., Hirano T., Taga T. et al. Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF). FASEB J1990; 4: 2860—2867.
18.
Szabo C.Role of nitric oxide in endotoxic shock. Ann NY Acad Sci1998; 851: 422—425.
19.
Lee S-T., Pineau T., Drago J. et al. Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol1995 ; 15: 3012—3022.
20.
Hill M., McCallum R.Identification of tumor necrosis factor as a transcriptional regulator of the phosphoenolpyruvate carboxykinase gene following endotoxin treatment of mice. Infect Immun1992; 60: 4040-4050.
21.
Altavilla D. , Squadrito F., Campo G. et al. The lazaroid, U-74389G, inhibits inducible nitric oxide synthase activity, reverses vascular failure and protects against endotoxin shock. Eur J Pharmacol1999; 369: 49—55.
22.
Ding A., Nathan C., Stuehr D.Release of reactive nitrogen intermediates from mouse peritoneal macrophages . J Immunol1988; 141: 2407—2412.
23.
Chawla A., Barak Y., Nagy L. et al. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med2001; 7: 48—52.
24.
Moore Krd, Fitzgerald M., Randow F. et al. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med2001; 7: 41—47.
25.
Nava E., Palmer R., Moncada S.The role of nitric oxide in endotoxic shock: effects of NG-monomethyl-L-arginine . J Cardiovasc Pharmacol1992; 20: 132—134.
26.
Colville-Nash P., Qureshi S., Willis D. et al. Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonist: correlation with induction of heme oxygenase I. J Immunol1998; 161: 978—984.
27.
Uchimura KN , Enjoji M., Irie M. et al. Activation of retinoic X receptor and peroxisome proliferator-activated receptor-gamma inhibits nitric oxide and tumor necrosis factor-alpha production in rat Kupffer cells. Hepatology2001; 33: 91—99.
28.
Libert C., Vink A., Coulie P. et al. Limited involvement of interleukin-6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin-6 or its receptor in various murine models. Eur J Immunol1992; 22: 2625—2630.
29.
Starnes HF, Pearch MK, Tewari A. et al. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor alpha challenge in mice. J Immunol1990; 145: 4185—4191.
30.
Martin C., Boisson C., Haccoun M. et al. Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma . Crit Care Med1997; 25: 1813—1819.
31.
Barton BE, Jackson JVProtective role of interleukin 6 in the lipopolysaccharide-galactosamine septic shock model. Infect Immun1993; 61: 1496—1499.
32.
Yoshizawa K-I. , Naruto B., Ida N. et al. Injection time of interleukin-6 determines fatal outcome in experimental endotoxin shock. J Interferon Cytokine Res1996; 16: 995—1000.
33.
Yoshimoto T., Nakanishi K., Hirose S. et al. High serum IL-6 level reflects susceptible status of the host to endotoxin and IL-1/tumor necrosis factor. J Immunol1992; 148: 3596—3603.
34.
Thieringer R. , Fenyk-Melody JE, LeGrand B. et al. Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses in macrophages to lipopolysaccharide in vitro or in vivo. J Immunol2000; 164: 1046—1054.
35.
Saltiel AR, Olefsky JMThiazolidinediones in the treatment of insulin resistance and type II diabetes . Diabetes1996; 45: 1661—1669.
36.
Hotamisligil G., Speigelman BMTumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes1994 ; 43: 1271—1278.
37.
Souza S., Yamamoto M., Franciosa M., et al. BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha . Diabetes1998; 47: 691—695.
38.
Hevener AL, Reichart D., Janez A. et al. Thiazolidinedione treatment prevents free-fatty acid-induced insulin resistance in male Wistar rats. Diabetes2001; 50: 2316—2322.
39.
Stith RD, McCallum REFailure of glucagon to induce hepatic phosphoenolpyruvatecarboxykinasein endotoxic shock. Circ Shock1988; 26: 267—272.
40.
Kelleher DL, Bagley GJ, Spitzer JJMetabolic and endocrine alterations following endotoxin administration in normal and diabetic rats. In: Biro Z et al. Homeostasis in Injury and Shock. Advances in Physiological Sciences. New York: Pergamon, 1981; 181—189.
41.
Feingold K. , Staprans I., Memon R. et al. Endotoxin rapidly induces changes in lipid metabolism that produce hypertriglyceridemia: low doses stimulate hepatic triglyceride production while high doses inhibit clearance. J Lipid Res1992; 33: 1765—1776.
42.
Grunfeld C. , Feingold K.The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy1991; 3: 143—158.
43.
Kawakami M. , Pekala P., Lane M., Cerami A.Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci USA1982; 82: 912—916.
44.
Kawakami M. , Cerami A.Studies of endotoxin-induced decrease in lipoprotein lipase activities. J Exp Med1981; 154: 631—639.
45.
Feingold K. , Funk J., Moser A. et al. Role for circulating lipoproteins in protection from endotoxin toxicity. Infect Immun1995; 63: 2041—2046.
46.
Reed LJ, Meunch HAA simple method for estimating 50% end points. Am J Hyg1938; 27: 493—499.
